ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 208.93M | 206.77M | 197.67M | 68.13M | 34.79M |
| Total Depreciation and Amortization | 7.91M | 7.90M | 8.05M | 8.21M | 8.36M |
| Total Amortization of Deferred Charges | 821.00K | 888.00K | 951.00K | 1.43M | 1.90M |
| Total Other Non-Cash Items | -58.70M | -63.57M | -69.46M | 36.94M | 36.53M |
| Change in Net Operating Assets | -82.26M | -50.77M | -18.54M | -28.66M | -8.57M |
| Cash from Operations | 76.71M | 101.22M | 118.67M | 86.05M | 73.01M |
| Capital Expenditure | -10.94M | -10.58M | -8.23M | -6.67M | -6.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -159.00K | -353.00K | -349.00K | -566.00K | -524.00K |
| Cash from Investing | -11.10M | -10.93M | -8.58M | -7.23M | -6.89M |
| Total Debt Issued | 30.00M | -- | -- | 135.00M | 135.00M |
| Total Debt Repaid | -90.00M | -60.00M | -60.00M | -188.59M | -158.59M |
| Issuance of Common Stock | 8.30M | 6.57M | 7.49M | 7.06M | 1.99M |
| Repurchase of Common Stock | -10.22M | -9.72M | -4.97M | -4.67M | -3.72M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.65M | -825.00K | -825.00K | -15.08M | -15.08M |
| Cash from Financing | -63.57M | -63.98M | -58.30M | -66.27M | -40.39M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.04M | 26.30M | 51.80M | 12.55M | 25.73M |